25 results
8-K
EX-10.1
NRBO
NeuroBo Pharmaceuticals Inc
14 Sep 22
Entry into a Material Definitive Agreement
5:11pm
their responsibilities thereunder, (v) oversee other research and Development-related activities with respect to the Licensed Products in the applicable Field
8-K
EX-10.3
widxce0 sjv
30 Dec 19
Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals
9:04pm
424B3
vxcf0oh1ewl
6 Nov 19
Prospectus supplement
9:15am
S-4/A
5mqhmu74gyw1ny8fvv
10 Oct 19
Registration of securities issued in business combination transactions (amended)
9:35pm
S-4
3oit2at96xehqjdvu
3 Sep 19
Registration of securities issued in business combination transactions
12:00am
S-4
EX-10.38
zca8hqvh6e3sqpt720
3 Sep 19
Registration of securities issued in business combination transactions
12:00am
8-K
EX-10.6
mdkcpsqn
25 Jul 19
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
6:38am
425
EX-10.6
8bquhg3m pu
25 Jul 19
Business combination disclosure
6:36am
8-K
EX-99.1
tplke
15 Mar 19
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
8:05am